Navigation Links
Hormone Reduces Mortality in Heart Patients With High BP
Date:3/29/2009

Relaxin cuts shortness of breath and trimmed hospital stays, phase 2 study concludes

SUNDAY, March 29 (HealthDay News) -- The hormone relaxin reduces shortness of breath and cardiovascular death in people with heart failure who also have high blood pressure, according to a phase 2 trial conducted in eight countries.

The study included 234 people who, within a few hours of arriving at a hospital, were randomly assigned to receive an intravenous infusion of a placebo or varying doses of relaxin -- 10, 30 100 or 250 micrograms/kilogram (µ/kg) -- a day.

Shortness of breath improved in 40 percent of those who were given 30 µ/kg, compared with 23 percent of those who received the placebo.

After 60 days, fewer people given 30 µ/kg of relaxin had died from a cardiovascular cause or had to be readmitted to the hospital because of heart or kidney failure than in the placebo group: 2.6 percent compared with 17.2 percent. After 180 days, there were no cardiovascular deaths in the relaxin group at this dosage, but 14.3 percent of the placebo group had died from cardiovascular causes, the study found.

The study also found that people in the relaxin 30 µ/kg group spent less time in the hospital than did those in the placebo group (10.2 days vs. 12 days) and lived longer after discharge (47.9 days vs. 44.2 days). No safety concerns were noted in the relaxin 30 µ/kg group.

The study was funded by Corthera, and several of the researchers worked for the biopharmaceutical company, which has the rights to develop and market relaxin. The findings were to be presented at the American College of Cardiology meeting in Orlando, Fla., and appear online and in an upcoming print issue of The Lancet.

Over time, standard therapy can resolve shortness of breath and high blood pressure caused by heart failure, but evidence from this study "suggests that early administration of this drug in addition to standard therapy might be associated with more rapid, sustained and complete resolution of acute heart failure, as well as with more favorable long-term outcomes," wrote Dr. John R. Teerlink, of the San Francisco Veterans Affairs Medical Center and his colleagues.

On the basis of the study's results, the researchers said they plan to conduct a phase 3 clinical trial of relaxin, at 30 µ/kg, in people with heart failure.

More information

The American Heart Association has more about heart failure.



-- Robert Preidt



SOURCE: The Lancet, news release, March 29, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Diplomat Specialty Pharmacy Expands National Growth Hormone Patient Care Program - Hires Denise Piro, RN, BSN
2. Hormone Might Help Restore Female Fertility
3. March 2009 Mayo Clinic Womens HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women
4. Male Hormone Replacement Company Renewman.com Critical of MLB for Testosterone Abuse Publicity
5. Obesity linked to hormone imbalance that impacts sexual quality of life
6. Hormone Drug May Help Drinkers Stay Sober
7. U of I study shows benefits of hormone found in fat tissue
8. Hormones May Help Shield Women from Parkinsons
9. UCSF Gallo Study Finds Hormone Disorder Drug Could Help Drinkers Stay Sober
10. Hormone linked to high blood pressure and blood vessel disease in African-Americans
11. Findings raise new questions about evolution of hormones in mammals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hormone Reduces Mortality in Heart Patients With High BP
(Date:5/4/2016)... Hills, CA (PRWEB) , ... May 04, 2016 , ... ... care that ex-supermodel Janice Dickinson needed following breast cancer surgery. In March 2016, the ... situ, a type of breast cancer that occurs in the milk ducts, according to ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... medical coding, billing and compliance. In upcoming months, AudioEducator has lined up some ... Every conference is designed to give complete compliance know-how and practical, easy-to-apply advice. ...
(Date:5/4/2016)... ... May 03, 2016 – (PRWEB) May ... and child products, today revealed the non-toxic benefits of its Tutti ... deal with teething pain is just part of the story. These ... are BPA-, PVC-, and phthalate-free. , “Many baby toys contain ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... they acquired Pocono Sterilizer, an equipment sterilization service and sales company located in ... provides medical and research-related equipment and asset management services to the medical and ...
(Date:5/4/2016)... Clara, California (PRWEB) , ... May 04, 2016 ... ... organized by United Scientific Group is scheduled on July 25-27, 2016 at Las ... and other health care professionals from educational institutes and research organizations across the ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... New Jersey , May 4, 2016 ... its successful completion of an alternative public offering (APO). ... wholly owned operating company, Valeritas, Inc. and a private ... common stock at $5.00 per share. Under ... on May 3, 2016, Valeritas Holdings, Inc. will trade ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Actinic Keratosis Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Actinic Keratosis market valuations and forecast, ...
(Date:5/3/2016)... 2016 Research and Markets has ... Cell Therapy Market Outlook 2020" report to their ... , ,Recombinant technology has improved significantly in past years ... developed in coming years. Many cancer drugs have been ... therapies are also expected to be developed with its ...
Breaking Medicine Technology: